ArticleHeart and vessels2016
Antiplatelet therapy in Takotsubo cardiomyopathy: does it improve cardiovascular outcomes during index event?
Article in Heart and vessels, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Prognostic impact of antiplatelet therapy in Takotsubo syndrome: a systematic review and meta-analysis of the literature.Heart failure reviews · 2022Pooled it
- Prognostic factors of Takotsubo cardiomyopathy: a systematic review.ESC heart failure · 2021Pooled it
- International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management.European heart journal · 2018Guideline
- Survival benefit of secondary prevention medical therapy in takotsubo cardiomyopathy: a Bayesian network meta-analysis.European heart journal open · 2025Article
- Effects of cardiovascular risk factors and pre-existing diseases on the short-term outcome of Takotsubo syndrome.Wiener klinische Wochenschrift · 2024Article
- Epidemiology, Pathophysiology, Diagnosis, and Principles of Management of Takotsubo Cardiomyopathy: A Review.Medical science monitor : international medical journal of experimental and clinical research · 2023Review
- Update of Takotsubo cardiomyopathy: Present experience and outlook for the future.International journal of cardiology. Heart & vasculature · 2022Review
- Inverted Takotsubo Syndrome With HELLP Syndrome: A Case Report.Frontiers in cardiovascular medicine · 2022Article
- Takotsubo cardiomyopathy in elderly female trauma patients: a case series.Journal of medical case reports · 2021Article
- Effect of aspirin in takotsubo syndrome: protocol of a systematic review and meta-analysis.BMJ open · 2021Article
- Takotsubo Syndrome: Uncovering Myths and Misconceptions.Current atherosclerosis reports · 2021Review
- [Inverted Takotsubo Syndrome due to Severe Scorpion Envenomation: Report of one Case].Medecine tropicale et sante internationale · 2021Article
- The Association Between Hyperlipidemia and In-Hospital Outcomes in Takotsubo Cardiomyopathy.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Article
- Takotsubo Syndrome: Clinical Manifestations, Etiology and Pathogenesis.Current cardiology reviews · 2021Article
- The Role of Antiplatelet Therapy in Patients With MINOCA.Frontiers in cardiovascular medicine · 2021Review
- Takotsubo syndrome: the broken-heart syndrome.The British journal of cardiology · 2021Review
- Reply to "SARS-CoV-2-associated Takotsubo is not necessarily triggered by the infection".International journal of cardiology. Heart & vasculature · 2020Article
- Review
- Atypical Presentation of Takotsubo Cardiomyopathy: Stroke as a Predisposing Factor.Medeniyet medical journal · 2020Article
- Novel Aspects of Classification, Prognosis and Therapy in Takotsubo Syndrome.European cardiology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasma catecholamines may play an important role in Takotsubo cardiomyopathy (TCM) pathophysiology. Patients with disproportionately high catecholamine responses to stressful events are prone to worse clinical outcomes. Catecholamines stimulate platelet activation and, therefore, may determine the clinical presentation and outcomes of TCM. We conducted a retrospective, descriptive study TCM patients admitted between 2003 and 2013 to Einstein Medical Center, Philadelphia, PA, USA and Danbury Hospital, Danbury, CT, USA. A total of 206 patients met Modified Mayo TCM criteria. Using a multiple logistic model, we tested whether aspirin, dual antiplatelet therapy (DAPT) aspirin + clopidogrel, beta blocker, statin, or ACE inhibitor use were independent predictors of major adverse cardiovascular events (MACE) during the index hospitalization. MACE was defined as in-hospital heart failure, in-hospital death, stroke or respiratory failure requiring mechanical ventilation. Incidence of in-hospital heart failure was 26.7 %, in-hospital death was 7.3 %, stroke was 7.3 % and MACE was 42.3 %. In a multiple logistic regression model (adjusted for gender, race, age, physical stressor, hypertension, diabetes, hyperlipidemia, smoking history, body mass index, initial left ventricular ejection fraction, single antiplatelet therapy, DAPT, beta blocker, statin, and ACE inhibitor) aspirin and DAPT at the time of hospitalization were independent predictors of a lower incidence of MACE during the index hospitalization (aspirin: OR 0.4, 95 % CI (0.16-0.9), P = 0.04; DAPT: OR 0.23; 95 % CI (0.1-0.55); P < 0.01. Physical stressor itself was also found to be an independent predictor of worse MACE: OR 5.1; 95 % CI (2.4-11.5); P < 0.01. In our study, aspirin and DAPT were independent predictors of a lower incidence of MACE during hospitalization for TCM. Prospective clinical trials are needed to confirm the findings of this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.